PM Philip Morris International
Great transition franchise, but at $186 the market already pays for a smoke-free win.
The story
PMI is a global tobacco franchise in which high-margin combustible cigarettes, with pricing power and slowly falling volumes, fund the move to smoke-free products: IQOS heated tobacco, ZYN nicotine pouches and VEEV. Its moat rests on brands, regulatory barriers to entry, distribution scale and IQOS device lock-in. It is a mature cash machine with a second growth engine, now mid-transition: smoke-free products are approaching 40%+ of revenue and are lifting group margins as they scale.
I kept all drivers from my previous take because the facts support them and did not change materially. TTM revenue of $43.1B implies about 6-8% growth, in line with the 7% Y1 assumption. Operating margin has reached 39.9% TTM, so converging to 41% as smoke-free scales remains reasonable, not a peak. Sales-to-capital stays at 2.5 for incremental reinvestment because the reported 1.11 is inflated by acquisition goodwill (Swedish Match). The 10-year horizon reflects a durable but regulated franchise, and terminal growth of 3% sits below the risk-free rate.
Value drivers
| Revenue growth (Y1) | 7.0% |
| Terminal growth | 3.0% |
| Forecast horizon | 10y |
| Target operating margin | 41.0% |
| Years to target margin | 5 |
| Sales-to-capital | 2.50 |
| Beta | 0.65 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 7.6% |
| Terminal WACC | 9.0% |
Valuation bridge
| PV of explicit FCFF | 120.32B |
| PV of terminal value | 152.37B |
| Equity value | 224.49B |
| ÷ shares → per share | $144.03 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 46.16B | 7.0% | 40.1% | 14.87B | 1.21B | 13.66B | 12.69B |
| 2 | 49.18B | 6.6% | 40.3% | 15.93B | 1.21B | 14.72B | 12.70B |
| 3 | 52.19B | 6.1% | 40.6% | 16.99B | 1.20B | 15.79B | 12.66B |
| 4 | 55.15B | 5.7% | 40.8% | 18.05B | 1.18B | 16.87B | 12.57B |
| 5 | 58.03B | 5.2% | 41.0% | 19.10B | 1.15B | 17.95B | 12.42B |
| 6 | 60.80B | 4.8% | 41.0% | 20.01B | 1.11B | 18.90B | 12.16B |
| 7 | 63.43B | 4.3% | 41.0% | 20.88B | 1.05B | 19.83B | 11.84B |
| 8 | 65.90B | 3.9% | 41.0% | 21.69B | 986.74M | 20.70B | 11.49B |
| 9 | 68.17B | 3.4% | 41.0% | 22.44B | 907.96M | 21.53B | 11.10B |
| 10 | 70.22B | 3.0% | 41.0% | 23.11B | 818.04M | 22.29B | 10.68B |
Key risks
- Regulatory or excise shocks to ZYN or IQOS (FDA flavor/nicotine caps, EU tobacco directive revisions, heated-tobacco tax parity)
- Combustible volume declines accelerating faster than pricing can offset, plus FX drag from emerging-market currencies
- High leverage ($44B net debt) and a payout-heavy dividend policy, which leave little room for missteps or rising rates
Catalysts
- ZYN US capacity expansion and international rollout keeping smoke-free growth in the double digits
- IQOS ILUMA US launch following FDA authorization, opening the largest profit pool